{"openapi":"3.0.0","servers":[{"url":"https://dev.burni.xn--7-c56d.com/"}],"info":{"title":"Burni API documentation","version":"v2.1.0","description":"Documentation for the REST API"},"paths":{"/fhir/MedicinalProductInteraction":{"post":{"operationId":"createMedicinalProductInteraction","tags":["MedicinalProductInteraction"],"summary":"create MedicinalProductInteraction resource.","parameters":[],"requestBody":{"content":{"application/fhir+json":{"schema":{"$ref":"#/components/schemas/createMedicinalProductInteraction"},"examples":{"json-example":{"value":{"resourceType":"MedicinalProductInteraction","id":"example","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative with Details</b></p><p><b>id</b>: example</p><p><b>description</b>: Inhibitors of CYP3A4 and P-gp\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\nequixaban Cmax.\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\nsection 4.4).\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.</p><blockquote><p><b>interactant</b></p><p><b>item</b>: ketoconazole <span>(Details : {http://ema.europa.eu/example/interactant code 'ketoconazole' = 'ketoconazole)</span></p></blockquote><blockquote><p><b>interactant</b></p><p><b>item</b>: itraconazole <span>(Details : {http://ema.europa.eu/example/interactant code 'itraconazole' = 'itraconazole)</span></p></blockquote><p><b>type</b>: StrongInhibitorofCYP3A4 <span>(Details : {http://ema.europa.eu/example/interactionsType code 'StrongInhibitorofCYP3A4' = 'StrongInhibitorofCYP3A4)</span></p><p><b>effect</b>: Increasedplasmaconcentrations <span>(Details : {http://ema.europa.eu/example/interactionseffect code 'Increasedplasmaconcentrations' = 'Increasedplasmaconcentrations)</span></p><p><b>management</b>: Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp <span>(Details )</span></p></div>"},"description":"Inhibitors of CYP3A4 and P-gp\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\nequixaban Cmax.\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\nsection 4.4).\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.","interactant":[{"itemCodeableConcept":{"coding":[{"system":"http://ema.europa.eu/example/interactant","code":"ketoconazole"}]}},{"itemCodeableConcept":{"coding":[{"system":"http://ema.europa.eu/example/interactant","code":"itraconazole"}]}}],"type":{"coding":[{"system":"http://ema.europa.eu/example/interactionsType","code":"StrongInhibitorofCYP3A4"}]},"effect":{"coding":[{"system":"http://ema.europa.eu/example/interactionseffect","code":"Increasedplasmaconcentrations"}]},"management":{"text":"Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp"},"meta":{"tag":[{"system":"http://terminology.hl7.org/CodeSystem/v3-ActReason","code":"HTEST","display":"test health data"}]}}}}},"application/fhir+xml":{"schema":{"$ref":"#/components/schemas/createMedicinalProductInteraction","xml":{"name":"MedicinalProductInteraction"}},"examples":{"xml-example":{"value":"\n<?xml version=\"1.0\" encoding=\"UTF-8\"?><MedicinalProductInteraction xmlns=\"http://hl7.org/fhir\"><id value=\"example\"/><meta><tag><system value=\"http://terminology.hl7.org/CodeSystem/v3-ActReason\"/><code value=\"HTEST\"/><display value=\"test health data\"/></tag></meta><text><status value=\"generated\"/><div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative with Details</b></p><p><b>id</b>: example</p><p><b>description</b>: Inhibitors of CYP3A4 and P-gp\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\nequixaban Cmax.\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\nsection 4.4).\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.</p><blockquote><p><b>interactant</b></p><p><b>item</b>: ketoconazole <span>(Details : {http://ema.europa.eu/example/interactant code 'ketoconazole' = 'ketoconazole)</span></p></blockquote><blockquote><p><b>interactant</b></p><p><b>item</b>: itraconazole <span>(Details : {http://ema.europa.eu/example/interactant code 'itraconazole' = 'itraconazole)</span></p></blockquote><p><b>type</b>: StrongInhibitorofCYP3A4 <span>(Details : {http://ema.europa.eu/example/interactionsType code 'StrongInhibitorofCYP3A4' = 'StrongInhibitorofCYP3A4)</span></p><p><b>effect</b>: Increasedplasmaconcentrations <span>(Details : {http://ema.europa.eu/example/interactionseffect code 'Increasedplasmaconcentrations' = 'Increasedplasmaconcentrations)</span></p><p><b>management</b>: Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp <span>(Details )</span></p></div></text><description value=\"Inhibitors of CYP3A4 and P-gp\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\nequixaban Cmax.\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\nsection 4.4).\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.\"/><interactant><itemCodeableConcept><coding><system value=\"http://ema.europa.eu/example/interactant\"/><code value=\"ketoconazole\"/></coding></itemCodeableConcept></interactant><interactant><itemCodeableConcept><coding><system value=\"http://ema.europa.eu/example/interactant\"/><code value=\"itraconazole\"/></coding></itemCodeableConcept></interactant><type><coding><system value=\"http://ema.europa.eu/example/interactionsType\"/><code value=\"StrongInhibitorofCYP3A4\"/></coding></type><effect><coding><system value=\"http://ema.europa.eu/example/interactionseffect\"/><code value=\"Increasedplasmaconcentrations\"/></coding></effect><management><text value=\"Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp\"/></management></MedicinalProductInteraction>"}}}}},"description":"create MedicinalProductInteraction resource.","responses":{"200":{"description":"successful operation","content":{"application/fhir+json":{"schema":{"type":"object","items":{"$ref":"#/components/schemas/FHIR-XML-RESOURCE"}},"examples":{"json-example":{"value":{"resourceType":"MedicinalProductInteraction","id":"34868be2-3b67-4938-8c82-de12c8506b93","description":"Inhibitors of CYP3A4 and P-gp\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\nequixaban Cmax.\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\nsection 4.4).\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.","interactant":[{"itemCodeableConcept":{"coding":[{"system":"http://ema.europa.eu/example/interactant","code":"ketoconazole"}]}},{"itemCodeableConcept":{"coding":[{"system":"http://ema.europa.eu/example/interactant","code":"itraconazole"}]}}],"type":{"coding":[{"system":"http://ema.europa.eu/example/interactionsType","code":"StrongInhibitorofCYP3A4"}]},"effect":{"coding":[{"system":"http://ema.europa.eu/example/interactionseffect","code":"Increasedplasmaconcentrations"}]},"management":{"text":"Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp"},"meta":{"tag":[{"system":"http://terminology.hl7.org/CodeSystem/v3-ActReason","code":"HTEST","display":"test health data"}],"versionId":"1","lastUpdated":"2022-02-13T22:30:17.988+08:00"}}}}},"application/fhir+xml":{"schema":{"type":"object","items":{"$ref":"#/components/schemas/FHIR-XML-RESOURCE"},"xml":{"name":"MedicinalProductInteraction"}},"examples":{"xml-example":{"value":"<?xml version=\"1.0\" encoding=\"UTF-8\"?><MedicinalProductInteraction xmlns=\"http://hl7.org/fhir\"><id value=\"936a22b3-5ea8-4f97-9105-300c41e8776b\"/><meta><versionId value=\"1\"/><lastUpdated value=\"2022-02-17T17:34:54.876+08:00\"/><tag><system value=\"http://terminology.hl7.org/CodeSystem/v3-ActReason\"/><code value=\"HTEST\"/><display value=\"test health data\"/></tag></meta><description value=\"Inhibitors of CYP3A4 and P-gp\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\nequixaban Cmax.\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\nsection 4.4).\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.\"/><interactant><itemCodeableConcept><coding><system value=\"http://ema.europa.eu/example/interactant\"/><code value=\"ketoconazole\"/></coding></itemCodeableConcept></interactant><interactant><itemCodeableConcept><coding><system value=\"http://ema.europa.eu/example/interactant\"/><code value=\"itraconazole\"/></coding></itemCodeableConcept></interactant><type><coding><system value=\"http://ema.europa.eu/example/interactionsType\"/><code value=\"StrongInhibitorofCYP3A4\"/></coding></type><effect><coding><system value=\"http://ema.europa.eu/example/interactionseffect\"/><code value=\"Increasedplasmaconcentrations\"/></coding></effect><management><text value=\"Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp\"/></management></MedicinalProductInteraction>"}}}}},"400":{"description":"error","content":{"application/fhir+json":{"schema":{"type":"object","items":{"$ref":"#/components/schemas/FHIR-XML-RESOURCE"}},"examples":{"Bad-Request-Response":{"value":{"resourceType":"OperationOutcome","issue":[{"severity":"error","code":"exception","diagnostics":"validation error, path `resourceType` is required"}]}}}},"application/fhir+xml":{"schema":{"type":"object","items":{"$ref":"#/components/schemas/FHIR-XML-RESOURCE"},"xml":{"name":"OperationOutcome"}},"examples":{"Bad-Request-Response":{"value":"\n<OperationOutcome xmlns='http://hl7.org/fhir'>\n<issue>\n    <severity value='error'/>\n    <code value='exception'/>\n    <diagnostics value='validation error, path `resourceType` is required'/>\n</issue>\n</OperationOutcome>"}}}}}},"x-codeSamples":[{"lang":"Shell","source":"#example from: https://chinlinlee.github.io/Burni/assets/FHIR/fhir-resource-examples/medicinalproductinteraction-example.json\ncurl --location --request POST 'http://burni.example.com/fhir/MedicinalProductInteraction \\' \n--header 'Content-Type: application/fhir+json' \\\n--data-raw '{\"resourceType\":\"MedicinalProductInteraction\",\"id\":\"34868be2-3b67-4938-8c82-de12c8506b93\",\"description\":\"Inhibitors of CYP3A4 and P-gp\\\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\\\nequixaban Cmax.\\\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\\\nsection 4.4).\\\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.\",\"interactant\":[{\"itemCodeableConcept\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactant\",\"code\":\"ketoconazole\"}]}},{\"itemCodeableConcept\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactant\",\"code\":\"itraconazole\"}]}}],\"type\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactionsType\",\"code\":\"StrongInhibitorofCYP3A4\"}]},\"effect\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactionseffect\",\"code\":\"Increasedplasmaconcentrations\"}]},\"management\":{\"text\":\"Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp\"},\"meta\":{\"tag\":[{\"system\":\"http://terminology.hl7.org/CodeSystem/v3-ActReason\",\"code\":\"HTEST\",\"display\":\"test health data\"}],\"versionId\":\"1\",\"lastUpdated\":\"2022-02-13T22:30:17.988+08:00\"}}'","label":"cURL"},{"lang":"JavaScript","source":" //example from: https://chinlinlee.github.io/Burni/assets/FHIR/fhir-resource-examples/medicinalproductinteraction-example.json\nconst axios = require('axios');\nconst data = {\"resourceType\":\"MedicinalProductInteraction\",\"id\":\"34868be2-3b67-4938-8c82-de12c8506b93\",\"description\":\"Inhibitors of CYP3A4 and P-gp\\\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\\\nequixaban Cmax.\\\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\\\nsection 4.4).\\\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.\",\"interactant\":[{\"itemCodeableConcept\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactant\",\"code\":\"ketoconazole\"}]}},{\"itemCodeableConcept\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactant\",\"code\":\"itraconazole\"}]}}],\"type\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactionsType\",\"code\":\"StrongInhibitorofCYP3A4\"}]},\"effect\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactionseffect\",\"code\":\"Increasedplasmaconcentrations\"}]},\"management\":{\"text\":\"Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp\"},\"meta\":{\"tag\":[{\"system\":\"http://terminology.hl7.org/CodeSystem/v3-ActReason\",\"code\":\"HTEST\",\"display\":\"test health data\"}],\"versionId\":\"1\",\"lastUpdated\":\"2022-02-13T22:30:17.988+08:00\"}}\nconst config = {\n    method: 'post',\n    url: 'http://burni.example.com/fhir/MedicinalProductInteraction',\n    headers: { \n        'Content-Type': 'application/fhir+json'\n    },\n    data: data\n};\n\naxios(config)\n.then(function (response) {\n    console.log(JSON.stringify(response.data));\n})\n.catch(function (error) {\n    console.log(error);\n});","label":"javascript Axios"}]}},"/fhir/MedicinalProductInteraction/{id}":{"delete":{"operationId":"deleteMedicinalProductInteraction","tags":["MedicinalProductInteraction"],"summary":"delete MedicinalProductInteraction resource by id.","parameters":[{"name":"id","in":"path","required":true,"schema":{"type":"string"},"description":"Resource ID in server"}],"responses":{"200":{"description":"successful operation","content":{"application/fhir+json":{"schema":{"type":"object","items":{"$ref":"#/components/schemas/FHIR-XML-RESOURCE"}},"examples":{"Success-Response":{"value":{"resourceType":"OperationOutcome","issue":[{"severity":"information","code":"informational","diagnostics":"delete MedicinalProductInteraction/34868be2-3b67-4938-8c82-de12c8506b93 successfully"}]}}}},"application/fhir+xml":{"schema":{"type":"object","items":{"$ref":"#/components/schemas/FHIR-XML-RESOURCE"},"xml":{"name":"OperationOutcome"}},"examples":{"Success-Response-XML":{"value":"<OperationOutcome xmlns='http://hl7.org/fhir'>\n    <issue>\n    <severity value='information'/>\n    <code value='informational'/>\n    <diagnostics value='delete MedicinalProductInteraction/34868be2-3b67-4938-8c82-de12c8506b93 successfully'/>\n    </issue>\n</OperationOutcome>"}}}}},"404":{"description":"error","content":{"application/fhir+json":{"schema":{"type":"object","items":{"$ref":"#/components/schemas/FHIR-XML-RESOURCE"}},"examples":{"Not-Found-Response":{"value":{"resourceType":"OperationOutcome","issue":[{"severity":"error","code":"exception","diagnostics":"The id->34868be2-3b67-4938-8c82-de12c8506b93 not found in MedicinalProductInteraction resource"}]}}}},"application/fhir+xml":{"schema":{"type":"object","items":{"$ref":"#/components/schemas/FHIR-XML-RESOURCE"},"xml":{"name":"OperationOutcome"}},"examples":{"Not-Found-Response-XML":{"value":"<OperationOutcome xmlns='http://hl7.org/fhir'>\n    <issue>\n    <severity value='error'/>\n    <code value='not-found'/>\n    <diagnostics value='The id-&gt;34868be2-3b67-4938-8c82-de12c8506b93  not found in MedicinalProductInteraction resource'/>\n    </issue>\n</OperationOutcome>"}}}}}},"x-codeSamples":[{"lang":"Shell","source":"#example from: https://chinlinlee.github.io/Burni/assets/FHIR/fhir-resource-examples/medicinalproductinteraction-example.json\ncurl --location --request DELETE 'http://burni.example.com/fhir/MedicinalProductInteraction/34868be2-3b67-4938-8c82-de12c8506b93'","label":"cURL"},{"lang":"JavaScript","source":" //example from: https://chinlinlee.github.io/Burni/assets/FHIR/fhir-resource-examples/medicinalproductinteraction-example.json\nconst axios = require('axios');\nconst config = {\n    method: 'delete',\n    url: 'http://burni.example.com/fhir/MedicinalProductInteraction/34868be2-3b67-4938-8c82-de12c8506b93'\n};\n\naxios(config)\n.then(function (response) {\n    console.log(JSON.stringify(response.data));\n})\n.catch(function (error) {\n    console.log(error);\n});","label":"javascript Axios"}]},"get":{"operationId":"readMedicinalProductInteraction","tags":["MedicinalProductInteraction"],"summary":"read MedicinalProductInteraction resource by id.","parameters":[{"name":"id","in":"path","required":true,"schema":{"type":"string"},"description":"Resource ID in server"}],"responses":{"200":{"description":"successful operation","content":{"application/fhir+json":{"schema":{"type":"object","items":{"$ref":"#/components/schemas/FHIR-XML-RESOURCE"}},"examples":{"Success-Response":{"value":{"resourceType":"MedicinalProductInteraction","id":"34868be2-3b67-4938-8c82-de12c8506b93","description":"Inhibitors of CYP3A4 and P-gp\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\nequixaban Cmax.\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\nsection 4.4).\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.","interactant":[{"itemCodeableConcept":{"coding":[{"system":"http://ema.europa.eu/example/interactant","code":"ketoconazole"}]}},{"itemCodeableConcept":{"coding":[{"system":"http://ema.europa.eu/example/interactant","code":"itraconazole"}]}}],"type":{"coding":[{"system":"http://ema.europa.eu/example/interactionsType","code":"StrongInhibitorofCYP3A4"}]},"effect":{"coding":[{"system":"http://ema.europa.eu/example/interactionseffect","code":"Increasedplasmaconcentrations"}]},"management":{"text":"Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp"},"meta":{"tag":[{"system":"http://terminology.hl7.org/CodeSystem/v3-ActReason","code":"HTEST","display":"test health data"}],"versionId":"1","lastUpdated":"2022-02-13T22:30:17.988+08:00"}}}}},"application/fhir+xml":{"schema":{"type":"object","items":{"$ref":"#/components/schemas/FHIR-XML-RESOURCE"},"xml":{"name":"MedicinalProductInteraction"}},"examples":{"Success-Response-XML":{"value":"<?xml version=\"1.0\" encoding=\"UTF-8\"?><MedicinalProductInteraction xmlns=\"http://hl7.org/fhir\"><id value=\"936a22b3-5ea8-4f97-9105-300c41e8776b\"/><meta><versionId value=\"1\"/><lastUpdated value=\"2022-02-17T17:34:54.876+08:00\"/><tag><system value=\"http://terminology.hl7.org/CodeSystem/v3-ActReason\"/><code value=\"HTEST\"/><display value=\"test health data\"/></tag></meta><description value=\"Inhibitors of CYP3A4 and P-gp\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\nequixaban Cmax.\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\nsection 4.4).\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.\"/><interactant><itemCodeableConcept><coding><system value=\"http://ema.europa.eu/example/interactant\"/><code value=\"ketoconazole\"/></coding></itemCodeableConcept></interactant><interactant><itemCodeableConcept><coding><system value=\"http://ema.europa.eu/example/interactant\"/><code value=\"itraconazole\"/></coding></itemCodeableConcept></interactant><type><coding><system value=\"http://ema.europa.eu/example/interactionsType\"/><code value=\"StrongInhibitorofCYP3A4\"/></coding></type><effect><coding><system value=\"http://ema.europa.eu/example/interactionseffect\"/><code value=\"Increasedplasmaconcentrations\"/></coding></effect><management><text value=\"Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp\"/></management></MedicinalProductInteraction>"}}}}},"404":{"description":"error","content":{"application/fhir+json":{"schema":{"type":"object","items":{"$ref":"#/components/schemas/FHIR-XML-RESOURCE"}},"examples":{"Not-Found-Response":{"value":{"resourceType":"OperationOutcome","issue":[{"severity":"error","code":"exception","diagnostics":"not found MedicinalProductInteraction/34868be2-3b67-4938-8c82-de12c8506b93"}]}}}},"application/fhir+xml":{"schema":{"type":"object","items":{"$ref":"#/components/schemas/FHIR-XML-RESOURCE"},"xml":{"name":"OperationOutcome"}},"examples":{"Not-Found-Response-XML":{"value":"<OperationOutcome xmlns='http://hl7.org/fhir'>\n<issue>\n    <severity value='error'/>\n    <code value='exception'/>\n    <diagnostics value='not found MedicinalProductInteraction/34868be2-3b67-4938-8c82-de12c8506b93'/>\n</issue>\n</OperationOutcome>"}}}}}},"x-codeSamples":[{"lang":"Shell","source":"#example from: https://chinlinlee.github.io/Burni/assets/FHIR/fhir-resource-examples/medicinalproductinteraction-example.json\ncurl --location --request GET 'http://burni.example.com/fhir/MedicinalProductInteraction/34868be2-3b67-4938-8c82-de12c8506b93'","label":"cURL"},{"lang":"JavaScript","source":" //example from: https://chinlinlee.github.io/Burni/assets/FHIR/fhir-resource-examples/medicinalproductinteraction-example.json\nconst axios = require('axios');\nconst config = {\n    method: 'get',\n    url: 'http://burni.example.com/fhir/MedicinalProductInteraction/34868be2-3b67-4938-8c82-de12c8506b93'\n};\n\naxios(config)\n.then(function (response) {\n    console.log(JSON.stringify(response.data));\n})\n.catch(function (error) {\n    console.log(error);\n});","label":"javascript Axios"}]},"put":{"operationId":"updateMedicinalProductInteraction","tags":["MedicinalProductInteraction"],"summary":"update MedicinalProductInteraction resource.","parameters":[{"name":"id","in":"path","required":true,"schema":{"type":"string"},"description":"Resource ID that you want to update"}],"requestBody":{"content":{"application/fhir+json":{"schema":{"$ref":"#/components/schemas/updateMedicinalProductInteraction"},"examples":{"json-example":{"value":{"resourceType":"MedicinalProductInteraction","id":"example","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative with Details</b></p><p><b>id</b>: example</p><p><b>description</b>: Inhibitors of CYP3A4 and P-gp\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\nequixaban Cmax.\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\nsection 4.4).\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.</p><blockquote><p><b>interactant</b></p><p><b>item</b>: ketoconazole <span>(Details : {http://ema.europa.eu/example/interactant code 'ketoconazole' = 'ketoconazole)</span></p></blockquote><blockquote><p><b>interactant</b></p><p><b>item</b>: itraconazole <span>(Details : {http://ema.europa.eu/example/interactant code 'itraconazole' = 'itraconazole)</span></p></blockquote><p><b>type</b>: StrongInhibitorofCYP3A4 <span>(Details : {http://ema.europa.eu/example/interactionsType code 'StrongInhibitorofCYP3A4' = 'StrongInhibitorofCYP3A4)</span></p><p><b>effect</b>: Increasedplasmaconcentrations <span>(Details : {http://ema.europa.eu/example/interactionseffect code 'Increasedplasmaconcentrations' = 'Increasedplasmaconcentrations)</span></p><p><b>management</b>: Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp <span>(Details )</span></p></div>"},"description":"Inhibitors of CYP3A4 and P-gp\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\nequixaban Cmax.\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\nsection 4.4).\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.","interactant":[{"itemCodeableConcept":{"coding":[{"system":"http://ema.europa.eu/example/interactant","code":"ketoconazole"}]}},{"itemCodeableConcept":{"coding":[{"system":"http://ema.europa.eu/example/interactant","code":"itraconazole"}]}}],"type":{"coding":[{"system":"http://ema.europa.eu/example/interactionsType","code":"StrongInhibitorofCYP3A4"}]},"effect":{"coding":[{"system":"http://ema.europa.eu/example/interactionseffect","code":"Increasedplasmaconcentrations"}]},"management":{"text":"Fa3DHffh0FEh4SC07X"},"meta":{"tag":[{"system":"http://terminology.hl7.org/CodeSystem/v3-ActReason","code":"HTEST","display":"T03Ke3vZhQ"}]}}}}},"application/fhir+xml":{"schema":{"$ref":"#/components/schemas/updateMedicinalProductInteraction","xml":{"name":"MedicinalProductInteraction"}},"examples":{"xml-example":{"value":"\n<?xml version=\"1.0\" encoding=\"UTF-8\"?><MedicinalProductInteraction xmlns=\"http://hl7.org/fhir\"><id value=\"example\"/><meta><tag><system value=\"http://terminology.hl7.org/CodeSystem/v3-ActReason\"/><code value=\"HTEST\"/><display value=\"T03Ke3vZhQ\"/></tag></meta><text><status value=\"generated\"/><div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative with Details</b></p><p><b>id</b>: example</p><p><b>description</b>: Inhibitors of CYP3A4 and P-gp\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\nequixaban Cmax.\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\nsection 4.4).\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.</p><blockquote><p><b>interactant</b></p><p><b>item</b>: ketoconazole <span>(Details : {http://ema.europa.eu/example/interactant code 'ketoconazole' = 'ketoconazole)</span></p></blockquote><blockquote><p><b>interactant</b></p><p><b>item</b>: itraconazole <span>(Details : {http://ema.europa.eu/example/interactant code 'itraconazole' = 'itraconazole)</span></p></blockquote><p><b>type</b>: StrongInhibitorofCYP3A4 <span>(Details : {http://ema.europa.eu/example/interactionsType code 'StrongInhibitorofCYP3A4' = 'StrongInhibitorofCYP3A4)</span></p><p><b>effect</b>: Increasedplasmaconcentrations <span>(Details : {http://ema.europa.eu/example/interactionseffect code 'Increasedplasmaconcentrations' = 'Increasedplasmaconcentrations)</span></p><p><b>management</b>: Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp <span>(Details )</span></p></div></text><description value=\"Inhibitors of CYP3A4 and P-gp\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\nequixaban Cmax.\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\nsection 4.4).\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.\"/><interactant><itemCodeableConcept><coding><system value=\"http://ema.europa.eu/example/interactant\"/><code value=\"ketoconazole\"/></coding></itemCodeableConcept></interactant><interactant><itemCodeableConcept><coding><system value=\"http://ema.europa.eu/example/interactant\"/><code value=\"itraconazole\"/></coding></itemCodeableConcept></interactant><type><coding><system value=\"http://ema.europa.eu/example/interactionsType\"/><code value=\"StrongInhibitorofCYP3A4\"/></coding></type><effect><coding><system value=\"http://ema.europa.eu/example/interactionseffect\"/><code value=\"Increasedplasmaconcentrations\"/></coding></effect><management><text value=\"Fa3DHffh0FEh4SC07X\"/></management></MedicinalProductInteraction>"}}}}},"description":"update MedicinalProductInteraction resource.","responses":{"200":{"description":"successful operation","content":{"application/fhir+json":{"schema":{"type":"object","items":{"$ref":"#/components/schemas/FHIR-XML-RESOURCE"}},"examples":{"json-example":{"value":{"resourceType":"MedicinalProductInteraction","id":"MedicinalProductInteraction-example","description":"Inhibitors of CYP3A4 and P-gp\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\nequixaban Cmax.\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\nsection 4.4).\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.","interactant":[{"itemCodeableConcept":{"coding":[{"system":"http://ema.europa.eu/example/interactant","code":"ketoconazole"}]}},{"itemCodeableConcept":{"coding":[{"system":"http://ema.europa.eu/example/interactant","code":"itraconazole"}]}}],"type":{"coding":[{"system":"http://ema.europa.eu/example/interactionsType","code":"StrongInhibitorofCYP3A4"}]},"effect":{"coding":[{"system":"http://ema.europa.eu/example/interactionseffect","code":"Increasedplasmaconcentrations"}]},"management":{"text":"Fa3DHffh0FEh4SC07X"},"meta":{"versionId":"20","lastUpdated":"2022-02-17T23:28:26.332+08:00"}}}}},"application/fhir+xml":{"schema":{"type":"object","items":{"$ref":"#/components/schemas/FHIR-XML-RESOURCE"},"xml":{"name":"MedicinalProductInteraction"}},"examples":{"xml-example":{"value":"<?xml version=\"1.0\" encoding=\"UTF-8\"?><MedicinalProductInteraction xmlns=\"http://hl7.org/fhir\"><id value=\"MedicinalProductInteraction-example\"/><meta><versionId value=\"22\"/><lastUpdated value=\"2022-02-18T00:39:39.688+08:00\"/></meta><description value=\"Inhibitors of CYP3A4 and P-gp\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\nequixaban Cmax.\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\nsection 4.4).\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.\"/><interactant><itemCodeableConcept><coding><system value=\"http://ema.europa.eu/example/interactant\"/><code value=\"ketoconazole\"/></coding></itemCodeableConcept></interactant><interactant><itemCodeableConcept><coding><system value=\"http://ema.europa.eu/example/interactant\"/><code value=\"itraconazole\"/></coding></itemCodeableConcept></interactant><type><coding><system value=\"http://ema.europa.eu/example/interactionsType\"/><code value=\"StrongInhibitorofCYP3A4\"/></coding></type><effect><coding><system value=\"http://ema.europa.eu/example/interactionseffect\"/><code value=\"Increasedplasmaconcentrations\"/></coding></effect><management><text value=\"Fa3DHffh0FEh4SC07X\"/></management></MedicinalProductInteraction>"}}}}},"400":{"description":"error","content":{"application/fhir+json":{"schema":{"type":"object","items":{"$ref":"#/components/schemas/FHIR-XML-RESOURCE"}},"examples":{"Bad-Request-Response":{"value":{"resourceType":"OperationOutcome","issue":[{"severity":"error","code":"exception","diagnostics":"validation error, path `resourceType` is required"}]}}}},"application/fhir+xml":{"schema":{"type":"object","items":{"$ref":"#/components/schemas/FHIR-XML-RESOURCE"},"xml":{"name":"OperationOutcome"}},"examples":{"Bad-Request-Response":{"value":"\n<OperationOutcome xmlns='http://hl7.org/fhir'>\n<issue>\n    <severity value='error'/>\n    <code value='exception'/>\n    <diagnostics value='validation error, path `resourceType` is required'/>\n</issue>\n</OperationOutcome>"}}}}}},"x-codeSamples":[{"lang":"Shell","source":"#example from: https://chinlinlee.github.io/Burni/assets/FHIR/fhir-resource-examples/medicinalproductinteraction-example.json\ncurl --location --request PUT 'http://burni.example.com/fhir/MedicinalProductInteraction/MedicinalProductInteraction-example \\' \n--header 'Content-Type: application/fhir+json' \\\n--data-raw '{\"resourceType\":\"MedicinalProductInteraction\",\"id\":\"example\",\"text\":{\"status\":\"generated\",\"div\":\"<div xmlns=\\\"http://www.w3.org/1999/xhtml\\\"><p><b>Generated Narrative with Details</b></p><p><b>id</b>: example</p><p><b>description</b>: Inhibitors of CYP3A4 and P-gp\\\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\\\nequixaban Cmax.\\\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\\\nsection 4.4).\\\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.</p><blockquote><p><b>interactant</b></p><p><b>item</b>: ketoconazole <span>(Details : {http://ema.europa.eu/example/interactant code 'ketoconazole' = 'ketoconazole)</span></p></blockquote><blockquote><p><b>interactant</b></p><p><b>item</b>: itraconazole <span>(Details : {http://ema.europa.eu/example/interactant code 'itraconazole' = 'itraconazole)</span></p></blockquote><p><b>type</b>: StrongInhibitorofCYP3A4 <span>(Details : {http://ema.europa.eu/example/interactionsType code 'StrongInhibitorofCYP3A4' = 'StrongInhibitorofCYP3A4)</span></p><p><b>effect</b>: Increasedplasmaconcentrations <span>(Details : {http://ema.europa.eu/example/interactionseffect code 'Increasedplasmaconcentrations' = 'Increasedplasmaconcentrations)</span></p><p><b>management</b>: Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp <span>(Details )</span></p></div>\"},\"description\":\"Inhibitors of CYP3A4 and P-gp\\\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\\\nequixaban Cmax.\\\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\\\nsection 4.4).\\\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.\",\"interactant\":[{\"itemCodeableConcept\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactant\",\"code\":\"ketoconazole\"}]}},{\"itemCodeableConcept\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactant\",\"code\":\"itraconazole\"}]}}],\"type\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactionsType\",\"code\":\"StrongInhibitorofCYP3A4\"}]},\"effect\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactionseffect\",\"code\":\"Increasedplasmaconcentrations\"}]},\"management\":{\"text\":\"Fa3DHffh0FEh4SC07X\"},\"meta\":{\"tag\":[{\"system\":\"http://terminology.hl7.org/CodeSystem/v3-ActReason\",\"code\":\"HTEST\",\"display\":\"T03Ke3vZhQ\"}]}}'","label":"cURL"},{"lang":"JavaScript","source":" //example from: https://chinlinlee.github.io/Burni/assets/FHIR/fhir-resource-examples/medicinalproductinteraction-example.json\nconst axios = require('axios');\nconst data = {\"resourceType\":\"MedicinalProductInteraction\",\"id\":\"MedicinalProductInteraction-example\",\"description\":\"Inhibitors of CYP3A4 and P-gp\\\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\\\nequixaban Cmax.\\\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\\\nsection 4.4).\\\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.\",\"interactant\":[{\"itemCodeableConcept\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactant\",\"code\":\"ketoconazole\"}]}},{\"itemCodeableConcept\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactant\",\"code\":\"itraconazole\"}]}}],\"type\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactionsType\",\"code\":\"StrongInhibitorofCYP3A4\"}]},\"effect\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactionseffect\",\"code\":\"Increasedplasmaconcentrations\"}]},\"management\":{\"text\":\"Fa3DHffh0FEh4SC07X\"},\"meta\":{\"versionId\":\"20\",\"lastUpdated\":\"2022-02-17T23:28:26.332+08:00\"}}\nconst config = {\n    method: 'put',\n    url: 'http://burni.example.com/fhir/MedicinalProductInteraction/MedicinalProductInteraction-example',\n    headers: { \n        'Content-Type': 'application/fhir+json'\n    },\n    data: data\n};\n\naxios(config)\n.then(function (response) {\n    console.log(JSON.stringify(response.data));\n})\n.catch(function (error) {\n    console.log(error);\n});","label":"javascript Axios"}]}}},"components":{"schemas":{"createMedicinalProductInteraction":{"properties":{"resourceType":{"type":"string","description":""}},"required":["resourceType"]},"FHIR-JSON-RESOURCE":{"properties":{}},"FHIR-XML-RESOURCE":{"properties":{}},"deleteMedicinalProductInteraction":{"properties":{"id":{"type":"string","description":"Resource ID in server"}},"required":["id"]},"readMedicinalProductInteraction":{"properties":{"id":{"type":"string","description":"Resource ID in server"}},"required":["id"]},"updateMedicinalProductInteraction":{"properties":{"id":{"type":"string","description":"Resource ID that you want to update"},"resourceType":{"type":"string","description":""}},"required":["id","resourceType"]}}}}